BRIEF-Staidson Beijing Biopharmaceuticals' Unit Filed Clinical Trial Applications For BDB-001 Injection

Feb 2 (Reuters) - Staidson Beijing BioPharmaceuticals Co Ltd :

* SAYS ITS UNIT HAS FILED TWO CLINICAL TRIAL APPLICATIONS FOR BDB-001 INJECTION FOR TREATMENT OF DISEASES CAUSED BY NEW CORONAVIRUS INFECTION Source text in Chinese: http://www.szse.cn/disclosure/listed/bulletinDetail/index.html?9dc2570c-6876-40b9-9a44-cbe763682f2f;

http://www.szse.cn/disclosure/listed/bulletinDetail/index.html?ae152bd9-292c-46a1-a824-0899e815ba9d Further company coverage: (Reporting by Hong Kong newsroom)